Mitochondrial dysfunction is known to play a central role in drug-induced hepatotoxicity, and thus early detection of mitochondrial toxicity is a critical component of initial drug development efforts. While immortalised cell lines are widely used for in vitro assessment of hepatotoxicity, cryopreserved primary human hepatocytes are a preferred model for drug safety screening.
In this App Note you will learn:
- How Agilent Seahorse technology provides a screening solution that is highly sensitive and direct.
- About the Agilent XF Mito Tox assay as a useful tool in the early detection of mitochondrial toxicity – a critical component of drug development efforts.
- How to use the Agilent Seahorse XF Mito Tox assay with primary human hepatocytes and predict DILI with sensitivity and ease.
- How to build a streamlined workflow with the Agilent Seahorse XF Mito Tox assay to understand the mitochondrial dysfunction role in drug-induced hepatotoxicity.
